Enter the following information to request a copy for the following item: Comparative cost-effectiveness analysis of avelumab plus axitinib versus pembrolizumab plus axitinib, ipilimumab plus nivolumab, and sunitnib for advanced renal cell carcinoma in the UK perspective

Requesting the following file: 16569.pdf